Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Technology appraisal guidance
Reference number: TA913
Published:
Following on from advice received from the company the timelines for this appraisal have been amended. Therefore, the committee meeting on 04 October 2022 has been rescheduled to take place on 6 December 2022.